Hepatitis C in Renal Disease, Hemodialysis and Transplantation

Description

Hepatitis C virus (HCV) infection is a major health problem worldwide, with currently over 150 million HCV-infected people on the five continents. Although there have been important advances in the diagnosis, prevention and therapy, the infection remains an important health problem in most countries.HCV infection is considered a systemic disease: Not only does it affect the liver, it can induce autoimmune, dermatological and renal disease. Moreover, soon after the discovery of HCV as the major cause of non-A non-B hepatitis, HCV infection was recognized as an important cause and consequence of chronic kidney disease. The publication at hand is an update on the most important topics concerning HCV infection, renal disease and problems with dialysis in the general population as well as in renal transplant patients. Also included is a chapter on the emerging problem of renal complications associated with HCV virus in patients with HIV infection.Containing contributions from a panel of internationally acclaimed experts, this publication is a timely update on HCV infection and the kidney.

Informations

• Publié par: S. Karger AG
• Date de parution: 23 janvier 2012
• Nombre de lectures: 0
• EAN13: 9783805598217
• Langue: English

Extrait

Hepatitis C in Renal Disease, Hemodialysis and Transplantation
Contributions to Nephrology
Vol. 176
Series Editor
Claudio Ronco    Vicenza
Hepatitis C in Renal Disease, Hemodialysis and Transplantation
Volume Editor
Jose M. Morales    Madrid
Co-Editors
Beatriz Domínguez-Gil    Madrid
Josep M. Campistol    Barcelona
Michel Jadoul    Brussels
Lionel Rostaing    Toulouse
David Roth    Miami, Fla.
9 figures and 8 tables, 2012

Basel • Freiburg • Paris • London • New York • New Delhi • Bangkok • Beijing • Tokyo • Kuala Lumpur • Singapore • Sydney
Contributions to Nephrology
(Founded 1975 by Geoffrey M. Berlyne)
______________________
Jose M. Morales
Instituto de Investigación
Hospital 12 de Octubre
ES-28001 Madrid
Library of Congress Cataloging-in-Publication Data
Hepatitis C in renal disease, hemodialysis and transplantation / volume editor, Jose M. Morales ; co-editors, Beatriz Domínguez-Gil … [et al.].
p.; cm. –– (Contributions to nephrology, ISSN 0302-5144 ; v. 176)
Includes bibliographical references and indexes.
ISBN 978-3-8055-9820-0 (hard cover: alk. paper) - - ISBN 978-3-8055-9821-7 (e-ISBN)
I. Morales, Jose M. (Jose Maria), 1949- II. Domínguez-Gil, Beatriz. III. Series: Contributions to nephrology; v. 176. 0302-5144
[DNLM: 1. Hepatitis C. 2. Kidney Diseases––complications. 3. Kidney Transplantation. 4. Renal Dialysis. W1 CO778UN v.176 2012'WC 536] 616.3'623––dc23
2011046047
Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2012 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Germany on acid-free and non-aging paper (ISO 9706) by Bosch Druck, Ergolding
ISSN 0302-5144
e-ISSN 1662-2782
ISBN 978-3-8055-9820-0
e-ISBN 978-3-8055-9821-7
Contents
VII Preface
Morales, J.M. (Madrid)
1 Hepatitis C: Epidemiology, Diagnosis, Natural History and Therapy
Pol, S.; Vallet-Pichard, A.; Corouge, M.; Mallet, V.O. (Paris)
10 Hepatitis C and Renal Disease: Epidemiology, Diagnosis, Pathogenesis and Therapy
Morales, J.M. (Madrid); Kamar, N.; Rostaing, L. (Toulouse)
24 Hepatitis C-Induced Renal Disease in Patients with AIDS: An Emergent Problem
Praga, M.; Gutiérrez Solís, E.; Morales, E. (Madrid)
35 Hepatitis C in Hemodialysis: Epidemiology and Prevention of Hepatitis C Virus Transmission
Jadoul, M. (Brussels); Barril, G. (Madrid)
42 Hepatitis C-Related Liver Disease in Dialysis Patients
Fabrizi, F. (Milan/Miami, Fla.); Dixit, V. (Miami, Fla.); Messa, P. (Milan); Martin, P. (Miami, Fla.)
54 Treatment of Hepatitis C in Dialysis Patients
Esforzado, N.; Campistol, J.M. (Barcelona)
66 Selection and Management of Hepatitis C Virus-Infected Patients for the Kidney Transplant Waiting List
Roth, D. (Miami, Fla.); Bloom, R. (Philadelphia, Pa.)
77 Kidney Transplantation in the Patient with Hepatitis C Virus Infection
Morales, J.M. (Madrid); Bloom, R. (Philadelphia, Pa.); Roth, D. (Miami, Fla.)
87 Treatment of Hepatitis C Virus Infection after Kidney Transplantation
Rostaing, L.; Weclawiak, H.; Izopet, J.; Kamar, N. (Toulouse)
97 Immunosuppression in Hepatitis C Virus-Infected Patients after Kidney Transplantation
Manuel, O. (Lausanne); Baid-Agrawal, S. (Berlin); Moradpour, D.; Pascual, M. (Lausanne)
108 Impact of Extrahepatic Complications (Diabetes and Glomerulonephritis) Associated with Hepatitis C Virus Infection after Renal Transplantation
Cruzado, J.M.; Bestard, O.; Grinyó, J.M. (Barcelona)
117 Renal Transplantation from Donors with a Positive Serology for Hepatitis C
Domínguez-Gil, B.; Esforzado, N.; Andrés, A.; Campistol, J.M.; Morales, J.M. (Madrid)
130 Author Index
131 Subject Index
Preface
Hepatitis C virus (HCV) infection is a major health problem worldwide. According to the reports, there are currently over 150 million HCV-infected people on the five continents. Although important advances in the diagnosis, prevention and therapy of HCV infection have been made, in most countries, particularly in the developing countries, it remains an important health problem.
HCV infection has been considered as a systemic disease: not only does it affect the liver, it can induce autoimmune, dermatological and renal disease. Not surprisingly, soon after the discovery of HCV as the major cause of non-A non-B hepatitis, HCV infection was recognized as an important cause and consequence of chronic kidney disease. For these reasons, Kidney Disease Improving Global Outcomes (KDIGO) decided to include HCV infection as an important topic to develop in nephrology, dialysis and transplantation. The document elaborated by a group of experts: ‘KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease’ [Kidney Int 2008;73(suppl 109):S1–S99] is the most important and complete contribution ever published on this topic.
Three years later after this publication, we had the initiative to review the most important recent news concerning HCV virus infection and nephrology, dialysis and transplantation. I personally contacted first Dr. Jadoul, Dr. Rostaing and Dr. Roth to start this project accepted by Karger Publishers as a new volume of Contributions in Nephrology . We have elaborated this publication including the most important topics concerning HCV infection, renal disease and problems with dialysis in the general population and also in renal transplant patients. We also included a chapter that discusses the emerging problem of renal complications associated with HCV virus in patients with HIV infection.
All international authors of this undertaking, most of them participants of KDIGO, are relevant investigators who have contributed to the knowledge of HCV infection in patients with chronic kidney disease. I acknowledge the important effort and contributions of all authors who made it all possible. Particularly, I acknowledge the Co-Editors’ enthusiasm with the project and criticism. Finally, I would like to express my gratitude to Karger Publishers for accepting our suggestion, to Novartis for their generous support and to my hospital and the Institute of Investigation of Hospital 12 de Octubre for their continuous stimulus.
Jose M. Morales, Madrid
Morales JM (ed): Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Contrib Nephrol. Basel, Karger, 2012, vol 176, pp 1-9
______________________
Hepatitis C: Epidemiology, Diagnosis, Natural History and Therapy
Stanislas Pol Anaïs Vallet-Pichard Marion Corouge Vincent O. Mallet
Université Paris Descartes, APHP, Hôpital Cochin, Unité d’Hépatologie, INSERM U-1016, Institut Cochin, Paris, France
______________________
Abstract
With an estimated prevalence of 3% in the world population (around 170 million infected individuals worldwide), hepatitis C virus (HCV) heavily burdens public health. Even though the incidence of new infections is declining, at least in industrialized countries where they are mainly restricted to intravenous drug users, morbidity and mortality (which means also HCV-induced costs) associated with HCV infection are expected to increase over the next decade. Models suggest that the incidence of hepatocellular carcinoma and HCV-related mortality will still increase until about 2015. The prevalence of the disease, the risk of progression of fibrosis to cirrhosis or hepatocellular carcinoma, mainly but not only in patients with liver comorbidities such as metabolic syndrome and/or heavy alcohol intake, evidences: (1) the need for a screening of chronic HCV infection as defined by both anti-HCV antibodies and detectable HCV RNA, (2) the evaluation of the extrahepatic (cryoglobulinemia-related vasculitis) or liver impact